Costs of First-Line Treatment With FOLFIRINOX, Modified FOLFIRINOX, and Gemcitabine With Nab-Paclitaxel in Metastatic Pancreatic Ductal Adenocarcinoma
To fully assess the economic impact of mPDAC in 1L treatment, it is essential to consider both the total cost and the individual cost components, such as chemotherapy drugs, administration, and supportive care costs.
Authors
- Syvart Dennen (ORCID: https://orcid.org/0000-0001-9872-4004)
- Ravi Kumar Paluri (ORCID: https://orcid.org/0000-0002-2317-7082)
- Martin Mašek (ORCID: https://orcid.org/0000-0003-1513-9358)
- Elizabeth Nagelhout
- Paul Cockrum
Institutions
- Atrium Health Wake Forest Baptist (US)
- Ipsen (France) (FR)
- Wake Forest Baptist Comprehensive Cancer Center
Publication Details
- Journal
- Journal of health economics and outcomes research
- Published
- 2025-08-22
- DOI
- https://doi.org/10.36469/001c.142403
- Primary Topic
- Pancreatic and Hepatic Oncology Research
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- Ipsen Biopharmaceuticals
- Ipsen